May vaptans contribute to the treatment of refractory ascites?
No abstract is available. To read the body of this article, please view the Full Text online.
PII: S0168-8278(10)00383-1
doi:10.1016/j.jhep.2010.04.003
© 2010 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis , 31 May 2010
